CN1235621C - Medicine composition for treating prostate proliferation, and its prepn. method - Google Patents
Medicine composition for treating prostate proliferation, and its prepn. method Download PDFInfo
- Publication number
- CN1235621C CN1235621C CN 02153461 CN02153461A CN1235621C CN 1235621 C CN1235621 C CN 1235621C CN 02153461 CN02153461 CN 02153461 CN 02153461 A CN02153461 A CN 02153461A CN 1235621 C CN1235621 C CN 1235621C
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- herba
- portions
- clear paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine composition for treating prostatic hyperplasia, which is characterized in that the medicine composition is made from the following raw medicinal materials of 83 to 248 portions of phellodendron, 83 to 248 portions of red peony root, 83 to 248 portions of angelica, 83 to 248 portions of hemlock parsley, 83 to 248 portions of glabrous greenbrier rhizome, 50 to 150 portions of prism tuber, 66 to 198 portions of water plantain, 66 to 198 portions of purslane, 66 to 198 portions of european verbena, 66 to 198 portions of saxifrage, 50 to 150 portions of radix bupleuri, 50 to 150 portions of cyathula root and 17 to 50 portions of liquorice by weight. The present invention also discloses a preparation method thereof.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of prostatic hyperplasia and preparation method thereof.
Chronic prostatitis is adult common, the frequently-occurring disease of male, and 20～40 years old person between twenty and fifty are particularly multiple, clinical chronic prostatitis and the prostate hyperplasia etc. of mostly being.The common sympton of chronic prostatitis is the puckery pain of frequent micturition, and urine drips white eventually, and dribble of urine is arranged, and the urine meaning reaches urethral orifice not to the utmost mucus or haircuts, simultaneously with the perineal position twinge, draws and testis, few abdomen and waist, or neurasthenia or sexual function change etc. are arranged; Prostate hyperplasia is then with dribble of urine, and the urine meaning is cardinal symptom not to the utmost.
The object of the invention is to provide a kind of evident in efficacy and prostatitic pharmaceutical composition of treatment of having no side effect and preparation method thereof.
Technical solution of the present invention is achieved in that
Following bulk drugs:
83～248 parts of 83～248 parts of Radix Angelicae Sinensis of 83～248 parts of Radix Paeoniae Rubra of Cortex Phellodendri
50～150 parts of 83～248 parts of rhizoma sparganic of 83～248 parts of Rhizoma Smilacis Glabraes of Rhizoma Chuanxiong
66～198 parts of 66～198 portions of Herba Verbenae of 66～198 portions of Herba Portulacaes of Rhizoma Alismatis
50～150 parts of 50～150 portions of Radix Cyathulaes of 66～198 parts of Radix Bupleuri of Herba Saxifragae
17～50 parts in Radix Glycyrrhizae
Get Cortex Phellodendri, Rhizoma Alismatis, Radix Angelicae Sinensis, Rhizoma Chuanxiong, add 4～8 times of amount 40～80% alcohol reflux 2～3 times, each 1～3 hour, filter, decompression filtrate recycling ethanol, it is standby to be condensed into clear paste; Other gets Radix Paeoniae Rubra, Rhizoma Smilacis Glabrae, rhizoma sparganic, Herba Portulacae, Herba Verbenae, Herba Saxifragae, Radix Bupleuri, Radix Cyathulae, Radix Glycyrrhizae, decocts with water 2～3 times, decocts 1～3 hour at every turn, filter, the merging filtrate concentrating under reduced pressure, gained clear paste and above-mentioned clear paste merge, and continue to be condensed into thick paste, drying under reduced pressure, dried cream powder is broken, adds starch or dextrin, granulates, incapsulate, promptly.
Through laboratory observation, chronic prostatitis rat model blood leukocytes counting is descended after taking pharmaceutical composition of the present invention, with model control group tangible statistical significance is arranged relatively; Increase all has utmost point significant inhibitory effect to chronic prostatitis rat model prostata tissue weight; The prostatic hyperplasia that the urogenital sinus implantation is caused adult mice has certain preventive effect; Mice there are antiinflammatory, analgesic activity; To 2, the 4-dinitrophenol causes rat fever that significant protective effect is arranged; Can obviously increase by 6 hours urine amount of rat; The infecting mouse infection symptoms was alleviated in 24 hours gradually, and the death time postpones, and the surviving animals number presents dose dependent.Above-mentioned experimental result shows that medicine of the present invention has the blood blood stasis dispelling, eliminating stasis and resolving masses, and sensible diuretic, the effect of clearing away heat-damp and promoting diuresis is used for chronic prostatitis, the treatment of damp-heat syndrome of holding concurrently of the stagnation of blood stasis of prostatic hyperplasia.
Pharmaceutical composition of the present invention has clearing away heat-damp and promoting diuresis, effects such as blood stasis-eliminating and stagnation-dissipating, the available chronic prostatitis that is used for due to the dampness and heat stasis, the treatment of disease diseases such as prostatic hyperplasia.
Experimental example 1: androlin is caused the outgrowth influence of rat prostate
50 of Wistar rats, male, be divided into five groups at random by body weight: normal control group, model control group, estradiol matched group, pharmaceutical composition high and low dose group of the present invention.Rat excision bilateral testes begins the subcutaneous injection androlin after 1 week of recuperating, and begins administration simultaneously, continuous 1 month.The last administration was put to death animal after 24 hours, separate to take out prostate, weighed and carried out between each group relatively.The result shows: the model group prostate is heavy apparently higher than the normal control group, and estradiol matched group prostate is heavy significantly to be reduced with model control group.Increase all has significant inhibitory effect to pharmaceutical composition of the present invention to rat prostate weight under 0.5-2g crude drug/kg dosage, points out pharmaceutical composition of the present invention that the rat chronic prostatitis is had the obvious treatment effect.
Experimental example 2: antiinflammatory action
Xylol causes the influence of mice ear
Get body weight 18-22g mice, irritate stomach and give pharmaceutical composition of the present invention, every day 1 time, continuous 7 days, be coated with dimethylbenzene 0.1ml in the Mus auris dextra back of the body in 30 minutes after the last administration, mice is put to death in the cervical vertebra dislocation after 2 hours, lay round auricle with card punch in left and right sides ear same area, weigh, ratio with interaural difference and left ear is the swelling degree, compare each group difference, the result shows: pharmaceutical composition extract of the present invention xylol induced mice ear swelling in 4-8g crude drug/kg dosage range has a significant effect, and sees the following form.
| Group | Number of animals | Contrast | Cause scorching ear weight (%) |
| Dosage group high dose group in the matched group aspirin low dose group | 10 10 10 10 10 | 100.0 100.0 100.0 100.0 100.0 | 189.6±39.7 132.9±28.5 151.1±31.6 134.0±24.6* 120.8±12.5** |
Compare * P＜0.05, * * P0.01 with matched group.
Embodiment 1:
Cortex Phellodendri 165g Radix Paeoniae Rubra 165g Radix Angelicae Sinensis 165g Rhizoma Chuanxiong 165g
Rhizoma Smilacis Glabrae 165g rhizoma sparganic 99g Rhizoma Alismatis 132g Herba Portulacae 132g
Herba Verbenae 132g Herba Saxifragae 132g Radix Bupleuri 99g Radix Cyathulae 99g
Radix Glycyrrhizae 33g
Get Cortex Phellodendri, Rhizoma Alismatis, Radix Angelicae Sinensis, Rhizoma Chuanxiong, add 6 times of amount 60% alcohol reflux secondaries, each 1.5 hours, filter, decompression filtrate recycling ethanol, it is standby to be condensed into clear paste; Other gets Radix Paeoniae Rubra, Rhizoma Smilacis Glabrae, rhizoma sparganic, Herba Portulacae, Herba Verbenae, Herba Saxifragae, Radix Bupleuri, Radix Cyathulae, Radix Glycyrrhizae, decocts with water secondary, decocts 1.5 hours at every turn, filter, the merging filtrate concentrating under reduced pressure, gained clear paste and above-mentioned clear paste merge, continue to be condensed into thick paste, drying under reduced pressure, dried cream powder is broken, adds starch to 400g, granulate, incapsulate, make 1000, promptly.
Embodiment 2:
Cortex Phellodendri 180g Radix Paeoniae Rubra 180g Radix Angelicae Sinensis 180g Rhizoma Chuanxiong 180g
Rhizoma Smilacis Glabrae 180g rhizoma sparganic 90g Rhizoma Alismatis 120g Herba Portulacae 120g
Herba Verbenae 120g Herba Saxifragae 120g Radix Bupleuri 90g Radix Cyathulae 90g
Radix Glycyrrhizae 40g
Get Cortex Phellodendri, Rhizoma Alismatis, Radix Angelicae Sinensis, Rhizoma Chuanxiong, add 6 times of amount 60% alcohol reflux secondaries, each 1.5 hours, filter, decompression filtrate recycling ethanol, it is standby to be condensed into clear paste; Other gets Radix Paeoniae Rubra, Rhizoma Smilacis Glabrae, rhizoma sparganic, Herba Portulacae, Herba Verbenae, Herba Saxifragae, Radix Bupleuri, Radix Cyathulae, Radix Glycyrrhizae, decocts with water secondary, decocts 1.5 hours at every turn, filter, the merging filtrate concentrating under reduced pressure, gained clear paste and above-mentioned clear paste merge, continue to be condensed into thick paste, drying under reduced pressure, dried cream powder is broken, adds starch to 400g, granulate, incapsulate, make 1000, promptly.
Claims (4)
1, a kind of pharmaceutical composition for the treatment of prostatic hyperplasia is characterized in that this pharmaceutical composition made by the following raw materials in weight medicine:
Cortex Phellodendri 180g, Radix Paeoniae Rubra 180g, Radix Angelicae Sinensis 180g, Rhizoma Chuanxiong 180g, Rhizoma Smilacis Glabrae 180g,
Rhizoma sparganic 90g, Rhizoma Alismatis 120g, Herba Portulacae 120g, Herba Verbenae 120g, Herba Saxifragae 120g,
Radix Bupleuri 90g, Radix Cyathulae 90g, Radix Glycyrrhizae 40g.
2, a kind of pharmaceutical composition for the treatment of prostatic hyperplasia is characterized in that this pharmaceutical composition made by the following raw materials in weight medicine:
Cortex Phellodendri 165g, Radix Paeoniae Rubra 165g, Radix Angelicae Sinensis 165g, Rhizoma Chuanxiong 165g, Rhizoma Smilacis Glabrae 165g,
Rhizoma sparganic 99g, Rhizoma Alismatis 132g, Herba Portulacae 132g, Herba Verbenae 132g, Herba Saxifragae 132g,
Radix Bupleuri 99g, Radix Cyathulae 99g, Radix Glycyrrhizae 33g.
3, the preparation of drug combination method of treatment prostatic hyperplasia as claimed in claim 1 or 2, it is characterized in that: get Cortex Phellodendri, Rhizoma Alismatis, Radix Angelicae Sinensis, Rhizoma Chuanxiong, add 4～8 times of amount 40～80% alcohol reflux 2～3 times, each 1～3 hour, filter, decompression filtrate recycling ethanol continues to concentrate, and it is standby to get clear paste; Other gets Radix Paeoniae Rubra, Rhizoma Smilacis Glabrae, rhizoma sparganic, Herba Portulacae, Herba Verbenae, Herba Saxifragae, Radix Bupleuri, Radix Cyathulae, Radix Glycyrrhizae, decocts with water 2～3 times, decocts 1～3 hour at every turn, filter, the merging filtrate concentrating under reduced pressure, gained clear paste and aforementioned clear paste merge, and continue to be condensed into thick paste, drying under reduced pressure, dried cream powder is broken, adds adjuvant, granulates, incapsulate, promptly.
4, the preparation of drug combination method of treatment prostatic hyperplasia as claimed in claim 3 is characterized in that: get Cortex Phellodendri, Rhizoma Alismatis, Radix Angelicae Sinensis, Rhizoma Chuanxiong, add 6 times of amount 60% alcohol reflux 2 times, each 1.5 hours, filter decompression filtrate recycling ethanol, continue to concentrate, it is standby to get clear paste; Other gets Radix Paeoniae Rubra, Rhizoma Smilacis Glabrae, rhizoma sparganic, Herba Portulacae, Herba Verbenae, Herba Saxifragae, Radix Bupleuri, Radix Cyathulae, Radix Glycyrrhizae, decocts with water 2 times, decocts 1.5 hours at every turn, filter, the merging filtrate concentrating under reduced pressure, gained clear paste and aforementioned clear paste merge, and continue to be condensed into thick paste, drying under reduced pressure, dried cream powder is broken, adds starch or dextrin, granulates, incapsulate, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153461 CN1235621C (en) | 2002-11-29 | 2002-11-29 | Medicine composition for treating prostate proliferation, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153461 CN1235621C (en) | 2002-11-29 | 2002-11-29 | Medicine composition for treating prostate proliferation, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1418686A CN1418686A (en) | 2003-05-21 |
| CN1235621C true CN1235621C (en) | 2006-01-11 |
Family
ID=4752261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02153461 Expired - Lifetime CN1235621C (en) | 2002-11-29 | 2002-11-29 | Medicine composition for treating prostate proliferation, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1235621C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100367928C (en) * | 2004-03-17 | 2008-02-13 | 咸阳步长医药科技发展有限公司 | Chinese materia medica preparation for treating hyperplasia of prostate and preparation method |
| CN100409873C (en) * | 2005-06-08 | 2008-08-13 | 胡硕泉 | Chinese herbal medicine for treating haemorrhoids and beri-beri |
| CN1824205B (en) * | 2005-12-22 | 2010-04-28 | 于浩芬 | Medicine for treating chronic prostatitis and its preparation method |
| CN105727098A (en) * | 2016-04-15 | 2016-07-06 | 宁波优美科新材料有限公司 | Drug for treating benign prostatic hyperplasia |
-
2002
- 2002-11-29 CN CN 02153461 patent/CN1235621C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1418686A (en) | 2003-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101596303B (en) | Pharmaceutical compound for curing prostatitis and prostate hyperplasia and preparation method and preparation thereof | |
| CN105169133B (en) | Treat the Chinese medicine preparation of psoriasis | |
| Wu et al. | Research progress on the treatment of epilepsy with traditional Chinese medicine | |
| CN104013929B (en) | Rheumatism pain relief medicine for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof | |
| CN1235621C (en) | Medicine composition for treating prostate proliferation, and its prepn. method | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN102552512B (en) | Traditional Chinese medicine used for treating hepatitis B | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN101002848B (en) | Medicine for treating recurrent uarthritis, and its preparing method | |
| CN102198230A (en) | Medicinal preparation for treating infantile repeated cold and preparation method thereof | |
| CN101342249A (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN101264314A (en) | Medicaments assembly for clearing heat and detoxication, activating blood circulation and removing stasis, and diminishing inflammation and reducing pain | |
| CN101152450B (en) | Dysuria releasing tablet and method for preparing the same | |
| CN111375038B (en) | Traditional Chinese medicine bath composition for treating psoriasis as well as preparation method and application thereof | |
| CN111407808B (en) | Traditional Chinese medicine composition and preparation method and pharmaceutical application thereof | |
| CN1814195A (en) | Chinese medicine composition for treating gynecopathy and use thereof | |
| CN105963597A (en) | Traditional Chinese medicine for treating oral ulcer | |
| CN1181879C (en) | Analgestic plaster | |
| CN104306784A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis as well as preparation method and application thereof | |
| Chen et al. | “Qingfei Paidu Decoction”—A Possible Choice of Phytotherapy for Severe Acute Respiratory Infection Caused by Coronavirus Disease-19 | |
| CN103157048A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN103055051B (en) | Liquid for treating burn and scald | |
| CN1103792A (en) | Proprietary Chinese medicine for curing stomach disease and the prepn. method | |
| CN110251564B (en) | External medicine for treating gouty arthritis and preparation method thereof | |
| CN104547246A (en) | Traditional Chinese medicine composition for treating haemorrhoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: QIYUANYIDE MEDICINES INST., BEIJING Free format text: FORMER OWNER: ZHANG HUIFANG Effective date: 20030812 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20030812 Address after: 100027, Beijing, Chaoyang District, East Third Ring Road, Xin 2, di Yang building, room 10, 1007A Applicant after: Beijing Qi Yuan Yi De Pharmaceuticals Research Center Address before: 100027, Beijing, Chaoyang District, East Third Ring Road, Xin 2, di Yang building, room 10, 1007A Applicant before: Zhang Huifang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BAODING BUCHANG TIANHAO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XIANYANG BUCHANG PHARMACEUTICAL CO., LTD. Effective date: 20100108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100108 Address after: Hebei Dingxing 86188 army hospital Patentee after: BAODING BUCHANG TIANHAO PHARMACEUTICAL Co.,Ltd. Address before: The west section of Xianyang City Weiyang Road No. 123 Patentee before: BUCHANG Group |
|
| C56 | Change in the name or address of the patentee |
Owner name: BAODING TIANHAO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: BAODING BUCHANG TIANHAO PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Xinghua 072650 Hebei province Dingxing County Road No. 128 Patentee after: BAODING TIANHAO PHARMACEUTICAL Co.,Ltd. Address before: 072650 Hebei province Dingxing County 86188 army hospital Patentee before: BAODING BUCHANG TIANHAO PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060111 |